10x Genomics (NASDAQ:TXG) has built a reputation as a trailblazer in recent years, with cutting-edge single-cell and spatial technologies. The firm's Chromium, Visium and Xenium platforms have ...

The Genomics Core houses a 10X Genomics Chromium iX which has the capacity to prepare GEMs for all standard 10X Genomics single cell pipelines: 3" scRNAseq single cell immune profiling fixed RNA ...

Genomics, Inc. (NASDAQ:TXG – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the ...

CEO Serge Saxonov, PhD, says provider of single cell, spatial, and in situ instruments expects to see benefits from sales ...

Additionally, the company’s Chromium installations exceeded expectations, further supporting the Buy rating. These factors together underpin the positive long-term outlook for 10x Genomics.

10x Genomics Inc is a life science technology ... The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others.

Weiss Ratings reaffirmed their sell (e+) rating on shares of 10x Genomics (NASDAQ:TXG – Free Report) in a report released on Saturday,Weiss Ratings reports. TXG has been the subject of several other ...

Specifically, the instrument and consumables revenues were higher than anticipated, with significant contributions from both Chromium and ... showcasing 10x Genomics’s ability to expand its ...

Increased cumulative instruments sold to more than 7,000 instruments as of the end of 2024, which includes over 5,800 Chromium instruments ... Co-founder and CEO of 10x Genomics.